Since DFO is hydrophilic, the development of the cream formulation involved incorporating Transcutol P (Gattefosse) to create emulsions which allow for effective penetration of the stratum corneum layer of the skin. Transcutol P is a highly purified form of diethylene glycol monoethyl ether (DEGEE) that serves as a safe solubilizer and enhancer for transdermal drug delivery.
22 (link) Transcutol P increases drug solubility in the vehicle (water) and penetration through the stratum corneum without disrupting physiologic lipid bilayer skin structures. Transcutol P has been approved by FDA as an inactive ingredient and has already been used in a variety of FDA approved human and veterinary drug products.
22 (link) Hydroxyethylcellulose was used as a gelling agent and mixed with water before finally being mixed with Transcutol P and DFO overnight in an overhead mixer to create the emulsion. The DFO cream was found to release approximately 46% at 6 h and approximately 83% after 24 h.
22 (link) Transcutol P increases drug solubility in the vehicle (water) and penetration through the stratum corneum without disrupting physiologic lipid bilayer skin structures. Transcutol P has been approved by FDA as an inactive ingredient and has already been used in a variety of FDA approved human and veterinary drug products.
22 (link) Hydroxyethylcellulose was used as a gelling agent and mixed with water before finally being mixed with Transcutol P and DFO overnight in an overhead mixer to create the emulsion. The DFO cream was found to release approximately 46% at 6 h and approximately 83% after 24 h.
Free full text: Click here
